1. Academic Validation
  2. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

  • J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342.
Jérôme Fagart 1 Alexander Hillisch Jessica Huyet Lars Bärfacker Michel Fay Ulrich Pleiss Elisabeth Pook Stefan Schäfer Marie-Edith Rafestin-Oblin Peter Kolkhof
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Bayer Schering Pharma AG, Global Drug Discovery, 42096 Wuppertal, Germany.
Abstract

Limitations of current steroidal Mineralocorticoid Receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines. Chemical optimization resulted in BR-4628, which displays high in vitro and in vivo MR potency as well as selectivity with respect to the other steroid hormone receptors and the L-type calcium channel. Biochemical studies demonstrated that BR-4628 forms complexes with MR that do not promote the recruitment of transcriptional co-regulators. Docking experiments, using the crystal structure of the MR ligand-binding domain in an agonist conformation, revealed that BR-4628 accommodates in the MR ligand-binding cavity differently in comparison with the classical steroidal MR antagonists. An alanine scanning mutagenesis approach, based on BR-4628 docking, allowed identifying its anchoring mode within the ligand-binding cavity. Altogether, we propose that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism. It represents the prototype of a new class of MR antagonists.

Figures